Cargando…

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People

Alaska Native and American Indian (AN/AI) people have unique pharmacogene variation that may affect warfarin disposition and therapeutic response. We performed targeted genotyping for cytochrome P450 (CYP)2C9, vitamin K epoxide oxidase reductase complex subunit 1 (VKORC1), CYP4F2,CYP4F11, and gamma‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henderson, Lindsay M., Robinson, Renee F., Ray, Lily, Khan, Burhan A., Li, Tianran, Dillard, Denise A., Schilling, Brian D., Mosley, Mike, Janssen, Patricia L., Fohner, Alison E., Rettie, Allan E., Thummel, Kenneth E., Thornton, Timothy A., Veenstra, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510382/ https://www.ncbi.nlm.nih.gov/pubmed/30821933 http://dx.doi.org/10.1111/cts.12611

Ejemplares similares

Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
por: Fohner, Alison E., et al.
Publicado: (2021)

Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People
por: Khan, Burhan A., et al.
Publicado: (2018)

Dietary and genetic influences on hemostasis in a Yup’ik Alaska Native population
por: Au, Nicholas T., et al.
Publicado: (2017)

In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup’ik Alaska Native Population
por: Henderson, Lindsay M., et al.
Publicado: (2021)

Prenatal alcohol exposure among Alaska Native/American Indian infants
por: Khan, Burhan A., et al.
Publicado: (2013)

Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke
por: Schaefer, Krista R., et al.
Publicado: (2021)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
por: He, Shiwei, et al.
Publicado: (2021)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

VKORC1 variants as significant predictors of warfarin dose in Emiratis
por: Al-Mahayri, Zeina N, et al.
Publicado: (2019)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
por: Al Ammari, Maha, et al.
Publicado: (2020)

Genetic Variation of VKORC1 and CYP4F2 Genes Related to Warfarin Maintenance Dose in Patients with Myocardial Infarction
por: Kringen, Marianne K., et al.
Publicado: (2011)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

Self-Determination in Health Research: An Alaska Native Example of Tribal Ownership and Research Regulation
por: Hiratsuka, Vanessa Y., et al.
Publicado: (2017)

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content
por: Shirasaka, Y, et al.
Publicado: (2016)

Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2018)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
por: Rafiee, Sajad, et al.
Publicado: (2017)

Alaska Native genomic research: perspectives from Alaska Native leaders, federal staff, and biomedical researchers
por: Hiratsuka, Vanessa Y., et al.
Publicado: (2020)

A Novel LC‐MS/MS Assay for Quantification of Des‐carboxy Prothrombin and Characterization of Warfarin‐Induced Changes
por: Basit, Abdul, et al.
Publicado: (2020)

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China
por: Yang, Dan, et al.
Publicado: (2018)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
por: Biswas, Mansij, et al.
Publicado: (2018)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
por: Aldiban, Weam, et al.
Publicado: (2022)

Alaska Native people's perceptions, understandings, and expectations for research involving biological specimens
por: Hiratsuka, Vanessa Y., et al.
Publicado: (2012)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects
por: Altawil, Yara, et al.
Publicado: (2023)

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
por: Zhang, Jinhua, et al.
Publicado: (2016)

Bi-cultural dynamics for risk and protective factors for cardiometabolic health in an Alaska Native (Yup’ik) population
por: Philip, Jacques, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hdf5n91ojq7o6a4ksgtkfpgvnj